Nitrate Ester Compounds for Muscle Tissue Nitric Oxide Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Muscular dystrophy, characterized by progressive muscle weakness and wasting, is exacerbated by reduced nitric oxide production due to dystrophin deficiency, impairing muscle regeneration and contraction, necessitating a method to deliver nitric oxide to muscle tissues for treatment and muscle function improvement.

Innovation Solution

A class of nitrate ester compounds capable of releasing nitric oxide, which also possess muscle relaxant properties, is administered to target muscle tissues, promoting myogenesis, reducing creatine kinase levels, and delaying dystrophic pathogenesis, thereby treating injured and diseased muscle tissue.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If nitric oxide is delivered to muscle tissues to promote regeneration and improve contraction, then muscle function and regeneration are improved, but the complexity of the treatment system increases

Engineering Contradiction:
Improvemuscle regenerationVSAvoidtreatment system complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses nitrate esters as intermediary compounds that deliver nitric oxide to muscle tissues. These compounds act as mediators between the external treatment and the target muscle cells, facilitating NO delivery without requiring complex delivery systems. The nitrate esters are administered systemically and naturally release NO at the target site, simplifying the overall treatment architecture while achieving reliable muscle regeneration effects.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If satellite cells are activated to enter the cell cycle for muscle repair, then muscle regeneration is enhanced, but energy consumption increases

Engineering Contradiction:
Improvemuscle repair rateVSAvoidenergy consumption
Core Design Contradiction:
ProductivityVSUse of energy by moving object

Solution Approach 1:

The patent employs nitric oxide to perform preliminary activation of satellite cells before the energy-intensive cell division and muscle repair processes begin. By pre-activating the cells and putting them into a ready state, the subsequent repair work becomes more efficient and less energetically costly. The NO treatment prepares the cellular machinery in advance, reducing the overall energy burden during the actual regeneration phase.

Inventive Principle:
Principle #10Preliminary action

3Object-affected harmful factors

If muscle fibers are relaxed to reduce contraction-induced damage, then muscle degeneration is suppressed, but muscle strength decreases

Engineering Contradiction:
Improvecontraction-induced damageVSAvoidmuscle strength
Core Design Contradiction:
Object-affected harmful factorsVSStrength

Solution Approach 1:

The patent implements periodic administration of nitrate esters to achieve cyclical muscle relaxation followed by normal function. This periodic treatment allows muscle fibers to relax during treatment phases, reducing contraction-induced damage, while maintaining strength during non-treatment phases. The oscillating treatment protocol creates alternating periods of protection and functional maintenance, resolving the contradiction between damage suppression and strength preservation.

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nitrate ester compounds increase myogenesis, improve exercise performance, and delay muscle degeneration in dystrophic muscles, providing therapeutic benefits for muscular dystrophy by enhancing muscle regeneration and relaxation.

Implementation Method 1

A class of nitrate ester compounds capable of releasing nitric oxide

Methodology Applied
Scientific EffectNitric oxide release from nitrate esters: Decomposition (biological)

Data Source

PatentUS9023890B2Nitrate esters and their use for the treatment of muscle and muscle related diseases
Publication Date: 2015.05.05 CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
  • US9023890B2 patent drawing
  • US9023890B2 patent drawing
  • US9023890B2 patent drawing

AI summary

Alkyl nitrate ester compounds are provided for the delivery of nitric oxide to targeted muscle tissues, and in particular, to normal and dystrophic muscles. In one aspect, nitrate ester compounds are provided having the following formula:wherein,R1 is ONO2, CH2ONO2, CnH2n+1OH, CnH2n+1OH, or CH2CH2CH3, or H;R2 is ONO2, CH2ONO2, Cn′H2n′+1OH, Cn′H2n′+1OH, CH2CH2CH3 or H; andR3 is ONO2, CH2ONO2, Cn′″H2n″+1OH, Cn″H2n″+1OH, CH2CH2CH3 or H;wherein n is an integer from 0 to 9, n′ is an integer from 0 to 9, and n″ is an integer from 0 to 9, and n+n′+n″≦9, and wherein at least one of R1, R2, and R3 is an ester nitrate selected from the group consisting of ONO2, CH2ONO2, and combinations thereof.